Recent Advances, Controversies, and Emerging Trends in MBC
Over the last 20 years, advances in HER2 targeting treatments, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have prolonged survival and changed the breast cancer treatment landscape. Success leads to more questions about optimal drug sequencing, mechanisms of resistance, and how to overcome that resistance. Let’s ask Dr. Stephanie Graff to help us tackle these topics and more.
2022 in Review: Best in MBC with Dr. Erika Hamilton
Welcome to the first Road to A Cure episode of Season 6. Our guest is the incomparable Dr. Erika Hamilton, a breast oncologist and researcher who, as she says herself, doesn’t shy away from difficult questions. In this episode, we get a review—subtype by subtype—of the biggest news over the past 15 months. Of course, we also talk about what is on the horizon in MBC.
ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?
Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.
RTAC: FES/Cerianna Screening for Estrogen Positive MBC
There’s a FDA- approved diagnostic imaging agent developed to comprehensively evaluate estrogen receptor-positive (ER+) lesions in recurrent or metastatic breast cancer as an adjunct to biopsy. By creating a “whole-body” picture of ER+ lesions, Cerianna may be a helpful diagnostic tool in helping oncologists better determine the most appropriate course of treatment. Learn more in this episode.
ASCO 2022: When the Dust Settles, Will ADCs Change MBC?
While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.
Dr. Shanu Modi: How to Get a Standing Ovation at ASCO?
MSK’s Dr. Shanu Modi, lead investigator on the DESTINY-Breast04 trial, talks with the Our MBC Life team about the trial’s standing ovation at ASCO, how to know if we’re HER2-low, and what this all means for us.
Season 5: Interviews, MBC101, Giveaways, and Much More…
The Our MBC Life senior producers and co-hosts, Victoria Goldberg and Natalia Green join Anne Woodward in a conversation about the upcoming season 5 of the podcast and some new things the team is doing and exciting details for very special giveaways for the Our MBC Life merchandise.
Dr. Nancy Lin: Are CNS Mets Becoming More Treatable? What’s New with STOP-HER2?
Brain metastases are unfortunately an all too common and devastating complication of breast cancer. The blood-brain barrier has long been a key obstacle to developing effective systemic therapies; however, newer agents are showing signs of overcoming this challenge. Dr. Nancy Lin explains.
ER Progression and Resistance: Causes, Consequences, and Hope
Endocrine therapy is an effective way to treat hormone-sensitive breast cancers, but de novo and acquired resistance to this treatment remains a major challenge. In this episode, the Our MBC Life team hears from two dynamic MSK oncologists Dr. Pedram Razavi and Dr. Komal Jhaveri on treatment strategies and the latest research around the problem of endocrine resistance.
Dr. Stephanie Graff: Understanding Progression
What does it mean when our cancer shows progression? And how do we know when that happens? The Our MBC Life team gets the lowdown from Dr. Stephanie L. Graff.
Dr. Lidia Schapira: Hey Doc, What Are You Telling Me?
What can we, as patients, do to strengthen our communication and relationships with our oncologists? This episode of Our MBC Life, the first in our MBC 101 series, includes perspectives, insights and suggestions from both sides of the critical doctor-patient relationship
Dr. Priya Kumthekar: Glimpses of Hope for Leptomeningeal Metastases
Co-hosts Victoria Goldberg and Dr. Paula Jayne sit down with neuro-oncologist Dr. Priya Kumthekar to talk about leptomeningeal metastases: what they are, how are they treated, and what research is upcoming, including a discussion on ANGled, the new Phase 3 trial for MBC patients newly diagnosed with leptomeningeal metastases.
Dr. Timothy Pluard: the Future of MBC Care is Already Here
The future of personalized care for those living with MBC is already here, and it is happening in Kansas City, Missouri. Dr. Timothy Pluard, Medical Director of the Kansas City’s Saint Luke’s Koontz Center for Advanced Breast Cancer is with us today and we’ll ask him how he and his team create an individualized, completely comprehensive plan for each woman.
MBC101 - what happens when MBC spreads to the brain?
On 10/12/21 Lianne Kraemer, an MBC patient advocate living with brain mets , and SHARE hosted two brilliant young clinicians from Moffitt in a discussion on management of breast cancer brain metastases. Today we are bringing you this webinar with our additional commentary. We will let you in on a little secret. This episode is a glimpse into how we envision the next season’s Road to a Cure. It will include more content with an educational angle for the newly diagnosed or those who are ready to take a deeper dive with us into the basics. We call it MBC101.
Road to a Cure - drug resistance
It is fitting that our 7th and last stop before the SABCS is back to NYC. Co-hosts Lisa Laudico and Ellen Landsberger talk with Dr Sarat Chandarlapaty, a leading Physician Scientist at MSKCC. As both a physician treating patients and a scientist in the lab, Dr. Chandarlapaty gives us an understanding of translational medicine, transferring what he learns from his patients back into the lab to answer questions that advance the treatment of metastatic breast cancer.
Road to a Cure - ABC with Dr. Fatima Cardoso
This is the sixth stop in our series Road to a Cure. From the start our goal for this series was not only to educate and give hope to every listener but also to ensure that each of these special interviews feels like an intimate conversation with our smartest friend who also happens to be an oncologist researcher. This episode will not disappoint., Co-hosts Victoria Goldberg and Lisa Laudico, sit down with the Director of the Breast Unit of the Champalimaud Clinical Center in Lisbon, Portugal, Dr. Fatima Cardoso.
Road to a Cure - ADC & SARM
How famous is Dr Hope Rugo? She belongs to a tiny elite group of oncologists who have their own Wikipedia page. Dr. Dennis Slamon is quite possibly the only other member. Enough said. No surprise that we can’t wait to hear what she has to say about a new class of drugs, known as ADCs and specifically, the first ADC for mTNBC that already has a nickname – Sassy (sacituzumab govitecan). Do you know what a SARM is? It is a special class of drugs for those who are Androgen Receptor (AR) positive. Listen and find out.
Road to a Cure - use of immunotherapy
This week we are visiting Dr Stephanie Goff at the NIH in Bethesda, Maryland. Dr Goff is a surgical oncologist and a senior member of a research team led by Dr. Steven A. Rosenberg, a man widely regarded as the father of immunotherapy. A friend, who knows a thing or two about this place. is joining us on this trip. Her name is Judy Perkins, and she is the first MBC patient who has been cured by a revolutionary immunotherapy treatment, known as adoptive cell therapy, that was administered by Dr Goff and her colleagues at the NCI.
Road to a Cure - Dr. Heather Parsons & Dr. Nancy Lin
The Road to a Cure series heads to Boston to have Senior Producer and Co-host, Victoria Goldberg and co-host Dr. Paula Jayne speak with Dr. Nancy Lin and Dr. Heather Parsons about the possibilities and the current barriers to considering a cure for HER2+ MBC. Dr. Parsons and Dr. Lin are medical oncologists and professors at Harvard Medical School. Dr. Lin is also the Director of the Metastatic Breast Cancer Program and the Associate Chief of the Division of Breast Oncology at Dana Farber Cancer Institute. While an amazing gift, long-term survival among some HER2+ patients can also sometimes bring special challenges. Given the higher prevalence of brain metastases among HER2+ patients, Drs. Lin and Parsons also discuss current research on brain mets, along with areas of promising overall MBC research for each subtype.
Road to a Cure - Dr. Sara Hurvitz
The Road to a Cure series gets on the redeye to LA to have Senior Producer and Co-host, Victoria Goldberg and co-host Kate Pfitzer speak with Dr. Sara Hurvitz. She talks about her perspective on where we are as we work for a cure, the HER2+ studies she is excited about, and other research that is intriguing as it relates to all subtypes